AR020691A1 - Derivados del acido 2,4-pentadienoico que tienen actividad selectiva para los receptores (rxr) del retinoide x - Google Patents

Derivados del acido 2,4-pentadienoico que tienen actividad selectiva para los receptores (rxr) del retinoide x

Info

Publication number
AR020691A1
AR020691A1 ARP990104996A ARP990104996A AR020691A1 AR 020691 A1 AR020691 A1 AR 020691A1 AR P990104996 A ARP990104996 A AR P990104996A AR P990104996 A ARP990104996 A AR P990104996A AR 020691 A1 AR020691 A1 AR 020691A1
Authority
AR
Argentina
Prior art keywords
rxr
pentadien
retinoid
receptors
derivatives
Prior art date
Application number
ARP990104996A
Other languages
English (en)
Spanish (es)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR020691A1 publication Critical patent/AR020691A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/50—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C07C69/618—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety having unsaturation outside the six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP990104996A 1998-10-01 1999-10-01 Derivados del acido 2,4-pentadienoico que tienen actividad selectiva para los receptores (rxr) del retinoide x AR020691A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/164,950 US6147224A (en) 1998-10-01 1998-10-01 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors

Publications (1)

Publication Number Publication Date
AR020691A1 true AR020691A1 (es) 2002-05-22

Family

ID=22596791

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990104996A AR020691A1 (es) 1998-10-01 1999-10-01 Derivados del acido 2,4-pentadienoico que tienen actividad selectiva para los receptores (rxr) del retinoide x

Country Status (16)

Country Link
US (1) US6147224A (enExample)
EP (2) EP1117628B1 (enExample)
JP (1) JP2002526516A (enExample)
KR (2) KR20010075457A (enExample)
CN (1) CN1328538A (enExample)
AR (1) AR020691A1 (enExample)
AT (1) ATE254593T1 (enExample)
AU (1) AU757932B2 (enExample)
BR (1) BR9914256A (enExample)
CA (1) CA2346034A1 (enExample)
DE (1) DE69912973T2 (enExample)
ES (1) ES2207339T3 (enExample)
NZ (1) NZ510528A (enExample)
TW (1) TW580494B (enExample)
WO (1) WO2000020370A1 (enExample)
ZA (1) ZA200102635B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
MXPA02002032A (es) 1999-08-27 2003-05-19 Ligand Pharm Inc Compuestos moduladores del receptor de androgeno y metodos.
EP1212322A2 (en) 1999-08-27 2002-06-12 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
US6593493B1 (en) 1999-09-14 2003-07-15 Ligand Pharmaceuticals, Inc. RXR modulators with improved pharmacologic profile
US6906046B2 (en) 2000-12-22 2005-06-14 Celltech R & D Inc. Pharmaceutical uses and synthesis of benzobicyclooctanes
CA2442366C (en) * 2001-03-27 2012-09-25 Circagen Pharmaceutical, Llc Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6388105B1 (en) * 2001-09-27 2002-05-14 Allergan Sales, Inc. Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6720423B2 (en) 2002-04-30 2004-04-13 Allergan, Inc. Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
EP1511477A4 (en) 2002-05-22 2008-04-09 Errant Gene Therapeutics Llc HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETO-EPOXYDE COMPOUNDS
JP2006508986A (ja) 2002-11-20 2006-03-16 エルラント ゲネ セラペウチクス エルエルシー ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法
US6683092B1 (en) 2003-04-09 2004-01-27 Allergan, Inc. [3-(c5-14alkyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-phenyl and [3-(c5-14alkyl-2-oxo-1,2,3,4- tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-heteroaryl derivatives having anti-tumor activity
US6734193B1 (en) 2003-06-03 2004-05-11 Allergan, Inc. (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
US6936636B2 (en) * 2003-06-26 2005-08-30 Allergan, Inc. 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
US6887896B1 (en) 2003-10-29 2005-05-03 Allergan, Inc. 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
LT1937244T (lt) 2005-09-30 2018-11-12 Io Therapeutics, Llc Vėžio gydymas specifiniais rxr agonistais
US20070185055A1 (en) * 2006-02-06 2007-08-09 Guang Liang Jiang Method for treating cachexia with retinoid ligands
CN110151745A (zh) 2011-12-13 2019-08-23 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
JP6492432B2 (ja) * 2013-07-09 2019-04-03 東ソー株式会社 アダマンチル基を有する環状アジン化合物、その製造方法、及びそれを構成成分とする有機電界発光素子
KR102149321B1 (ko) 2015-10-31 2020-08-28 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
NZ745704A (en) 2016-03-10 2019-04-26 Io Therapeutics Inc Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
KR102549273B1 (ko) 2016-03-10 2023-06-28 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
EP3684348A4 (en) 2017-09-20 2021-08-18 IO Therapeutics, Inc. TREATMENT OF DISEASES WITH ETERS FROM SELECTIVE RXR AGONISTS
KR102715396B1 (ko) * 2017-11-17 2024-10-08 아이오 테라퓨틱스, 인크. 레티노이드 x 수용체 특이적 레티노이드의 제조를 위한 화합물 및 합성 방법
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
EP4444287A4 (en) 2021-12-07 2025-05-28 Io Therapeutics, Inc. USE OF AN RXR AGONIST AND TAXANES FOR THE TREATMENT OF HER2+ CANCER
KR20240115316A (ko) 2021-12-07 2024-07-25 아이오 테라퓨틱스, 인크. 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826760D0 (en) * 1988-11-16 1988-12-21 Wellcome Found Pesticides
DE617614T1 (de) * 1991-12-18 1995-06-08 Baylor College Of Medicine, Houston, Tex. Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen.
DE69333894D1 (de) * 1992-04-22 2005-12-01 Ligand Pharm Inc Verbindungen mit Retinoid x rezeptorselektivität
ES2129115T3 (es) * 1993-01-11 1999-06-01 Ligand Pharm Inc Compuestos que tienen actividad selectiva para los receptores de retinoides x, y medios para la modulacion de procesos mediados por receptores de retinoides x.
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
KR100363545B1 (ko) * 1994-08-10 2003-02-19 에프. 호프만-라 로슈 아게 레틴산x-수용체리간드
IL116259A (en) * 1994-12-19 2000-07-16 American Cyanamid Co Analogs of 9-cis retinoic acid and their use
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US5543534A (en) * 1994-12-29 1996-08-06 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5675033A (en) * 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
AU726450B2 (en) * 1995-10-06 2000-11-09 Ligand Pharmaceuticals Incorporated Dimer-selective RXR modulators and methods for their use
US5723666A (en) * 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
CN1337931A (zh) * 1999-03-08 2002-02-27 巴斯利尔药物股份公司 类维生素a拮抗剂及其用途

Also Published As

Publication number Publication date
NZ510528A (en) 2003-04-29
EP1117628A1 (en) 2001-07-25
EP1117628B1 (en) 2003-11-19
KR20060118367A (ko) 2006-11-23
EP1388534A3 (en) 2004-02-25
JP2002526516A (ja) 2002-08-20
DE69912973T2 (de) 2004-07-22
EP1388534A2 (en) 2004-02-11
CA2346034A1 (en) 2000-04-13
BR9914256A (pt) 2001-07-03
AU6051399A (en) 2000-04-26
ZA200102635B (en) 2002-10-18
CN1328538A (zh) 2001-12-26
KR20010075457A (ko) 2001-08-09
US6147224A (en) 2000-11-14
AU757932B2 (en) 2003-03-13
TW580494B (en) 2004-03-21
ES2207339T3 (es) 2004-05-16
DE69912973D1 (de) 2003-12-24
ATE254593T1 (de) 2003-12-15
HK1039477A1 (en) 2002-04-26
WO2000020370A1 (en) 2000-04-13

Similar Documents

Publication Publication Date Title
ES2000842A6 (es) Un procedimiento para la preparacion de analogos semisinteticos de compactina y mevinolina
MX9303158A (es) Derivados de aminoquinolona substituidos con grupoarilo o con un grupo heterociclico aromatico; y agente anti-vih.
ES454405A1 (es) Procedimiento para la preparacion de derivados de quinazoli-na.
ES475240A1 (es) Un procedimiento de compuestos polienicos.
ES2171040T3 (es) Derivados de esteres hidroxiaceticos y su utilizacion como intermediarios de sintesis.
BR9914696A (pt) Composto, processo para tratamento de distúrbio mediado por ciclo-oxigenase-2 em um indivìduo, e, composição farmacêutica
DK1485359T3 (da) Natriumkanalblokkere
AR017730A1 (es) Compuestos derivados biciclicos del acido hidroxamico, composiciones que los contienen y uso de los mismos para la preparacion de medicamentos
AR245447A1 (es) Procedimiento para preparar derivados de 2,4-diamino-5-(biciclo-sustituido)metilpirimidinas.
BR9914256A (pt) Derivados de ácido 2,4-pentadienóico tendo atividade seletiva para receptores de retinóide x (rxr)
ES2136037A1 (es) Inhibidores de sulfamida-metaloproteasa
ES8600210A1 (es) Un procedimiento para la preparacion de nuevos derivados de arilamida
EA200401053A1 (ru) Оксо-азабициклические соединения
ES521191A0 (es) Procedimiento de preparacion de polimetileno-iminas disustituidas y de sus sales de adicion con acidos apropiados.
GT199900011A (es) Nuevos derivados del acido dihidroxihexanoico
DK0656001T3 (da) Nye 2-substituerede indan-2-mercaptoacetylamid-tricycliske derivater til anvendelse som enkefalinasehæmmere
ES2056808T3 (es) Derivados de antraciclina activos citostaticamente.
MX9304820A (es) Derivados de 1, 4-benzodioxano, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
FI812804L (fi) 2-(1,4-bensodioxan-2-ylalkyl)-imidazoler anvaendbara som antidepressiva laekemedel
ES462173A1 (es) Procedimiento para la preparacion de derivados de acido 7-a-cilamino-8-oxo-3-oxa-1-azabiciclo-(4,2,0)-octan-2-carboxili-co.
ES2180751T3 (es) Inhibidor de metastasis de cancer.
ES2038656T3 (es) Derivados de la tiometilpenicilina substituidos en beta y su preparacion y uso.
ES2068497T3 (es) Derivados de urea, su produccion, y composiciones farmaceuticas que los contienen.
NO963369D0 (no) Nye indan-2-mercaptoacetylamid-disulfidderivater som er anvendbare som inhibitorer av enkefalinase
ES2127191T3 (es) Derivados de diamino-s-triazinona.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal